Fabry disease: Clinical outcomes of agalsidase enzyme replacement therapies [4]

International Journal of Clinical Practice

Volumn 61, Issue 7, 2007, Pages 1234-1235

  Wanner, C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; PLACEBO;

CLINICAL TRIAL; DISEASE COURSE; ENZYME REPLACEMENT; FABRY DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LETTER; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

ALPHA-GALACTOSIDASE; FABRY DISEASE; HUMANS; ISOENZYMES; TREATMENT OUTCOME;

EID: 34250660217     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01399.x     Document Type: Letter

References (7)

1. Lidove O, Joly D, Barbey F et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007 61: 293 302.
2. ReplagalTM (agalsidase alfa) Briefing Document prepared by TKT, Inc for the Endocrinologic and Metabolic Drugs Advisory Committee Meeting, 14 January 2003. http://www.fda.gov/Ohrms/Dockets/AC/03/briefing/ 3917B2_01_TKT%20Replagal%20Background%20.pdf
3. Endocrinologic and Metabolic Drugs Advisory Committee Transcript Meeting, 14 January 2003. http:///www.fda.gov/ohrms/dockets/ac/03/transcripts/3917T2.doc
4. Schiffmann R, Kopp JB, Austin HA III. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001 285: 2743 9.
5. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001 345: 9 16.
6. MacDermot. Enzyme replacement therapy therapy reverses the cardiomyopathy of Fabry disease; results of a randomized, double blind, placebo controlled trial [abstract]. Eur J Hum Genet 2001 91: C074.
7. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007 146: 77 86.